Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 21

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 21
---
, will
be sufficient to enable us to fund our operating expenses and capital expenditure requirements through March 2025 without giving effect
to the proceeds from this offering. Even if this offering is completed, we expect that we will require substantial additional capital
to commercialize our Gelrin hydrogel platform and any future product candidates. In addition, our operating plans may change as a result
of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding
requirements will depend on many factors, including but not limited to:

| ● | the progress, results and                                             
 costs of our ongoing and planned studies and pivotal clinical trials; |

| ● | the cost, timing and outcomes                                                           
 of regulatory review of our Gelrin hydrogel platform and any future product candidates; |

<div align='center'>16</div>

| ● | the costs of manufacturing                                                                  
 product candidates, including costs related to engaging third-party manufacturers therefor; |

| ● | the scope, progress, results                                                                                                        
 and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other 
 product candidates that we may develop or otherwise obtain in the future;                                                           |

| ● | the cost of our future                                                                                                                    
 activities, including establishing sales, marketing and distribution capabilities for any product or product candidates in any particular 
 geography where we receive marketing approval for such product candidates;                                                                |

| ● | the terms and timing of                                                    
 any collaborative, licensing and other arrangements that we may establish; |

| ● | the costs of preparing,                                                                                                           
 filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual 
 property-related claims; and                                                                                                      |

| ● | the level of revenue, if                                                                               
 any, received from commercial sales of any product candidates for which we receive marketing approval. |

Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our Gelrin hydrogel platform and any future product candidates and any future product candidates. In addition, we cannot guarantee that
future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing
may adversely affect the holdings or the rights of holders of our securities and the issuance of additional securities, whether equity
or debt, by us, or the possibility of such issuance, may cause the market price of our Ordinary Shares to decline.